Rugiet Launches Testosterone Therapy After Surpassing $100M in 2025 Revenue

Rugiet has launched a testosterone replacement therapy (TRT) program, expanding its services beyond erectile dysfunction treatment. The Austin-based company said the rollout follows more than $100 million in revenue in 2025 and comes alongside a broader brand refresh.

The new TRT offering includes enclomiphene as well as oral, injectable, and topical testosterone therapies. According to the company, the program includes lab testing, physician evaluations, and personalized treatment plans for eligible patients. Rugiet is best known for Ready®, its 3-in-1 erectile dysfunction treatment, and says it has treated more than 400,000 patients since launching in 2020.

The company said its expansion into testosterone therapy reflects demand from patients whose sexual health concerns may overlap with broader physiological issues. Rugiet framed the new program as part of a wider push into men’s health categories beyond sexual performance, with its existing areas now including sleep, weight management, and testosterone.

The TRT launch also coincides with a new brand identity developed with Pentagram on branding and Alright Studio on web design. Rugiet said the rebrand is intended to support its positioning as a broader men’s healthcare company focused on what it describes as “performance medicine for men.”